波士顿标准2.0版在脑出血患者中诊断脑淀粉样血管病的验证
回顾性单中心队列研究纳入186例自发性脑出血行手术清除和脑活检的患者,验证波士顿标准2.0版诊断脑淀粉样血管病的效能。2.0版对很可能的脑淀粉样血管病敏感性高于1.5版(0.75 vs 0.57),特异性相近(0.96 vs 0.99)。非出血标志物半卵圆中心可见血管周围间隙与病理确诊的脑淀粉样血管病强相关(OR 5.49)。
要点
- 波士顿标准2.0版对很可能的脑淀粉样血管病敏感性0.75,高于1.5版的0.57。
- 2.0版特异性0.96,与1.5版的0.99相近。
- 半卵圆中心可见血管周围间隙与脑淀粉样血管病强相关(OR 5.49,95%CI 2.37-13.06)。
核心结论
- 波士顿标准2.0版提高了很可能的脑淀粉样血管病的诊断敏感性,且未降低特异性,主要得益于纳入半卵圆中心可见血管周围间隙等非出血标志物。
研究设计与样本
- 回顾性单中心队列研究,2015年至2021年在西奈山医疗系统开展,纳入186例自发性脑出血行手术清除、脑活检且有术前MRI的患者,以改良Vonsattel分级病理确诊脑淀粉样血管病。
主要发现
- 186例患者中位年龄63岁,女性占38%,24%病理确诊脑淀粉样血管病。
- 很可能的脑淀粉样血管病:2.0版敏感性0.75 vs 1.5版0.57,特异性0.96 vs 0.99。
- 可能的脑淀粉样血管病:2.0版敏感性0.82 vs 1.5版0.77,特异性0.84 vs 0.87。
- 皮质表面铁沉积与脑淀粉样血管病相关(OR 4.14,95%CI 1.35-13.00,p=0.013),脑叶脑微出血相关(OR 3.03,95%CI 1.31-7.10,p=0.009)。
- 半卵圆中心可见血管周围间隙强相关(OR 5.49,95%CI 2.37-13.06,p<0.001),多发点状白质高信号不相关(OR 1.10,95%CI 0.45-2.56,p=0.834)。
关键数值与推荐
- 很可能的脑淀粉样血管病诊断:2.0版敏感性0.75、特异性0.96;1.5版敏感性0.57、特异性0.99。
- 可能的脑淀粉样血管病诊断:2.0版敏感性0.82、特异性0.84;1.5版敏感性0.77、特异性0.87。
临床怎么用
- 原文未据此给出推荐。
局限性
- 回顾性设计。
- 缺乏正式的评价者间信度测量。
- 样本量有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Cerebral amyloid angiopathy (CAA) is a leading cause of lobar intracerebral hemorrhage (ICH) in older individuals, associated with significant morbidity and recurrence. The updated Boston criteria version 2.0 (v2.0) incorporate new MRI biomarkers to improve diagnostic accuracy. This study aimed to validate the diagnostic performance of v2.0 compared with version 1.5 (v1.5) in patients with spontaneous ICH undergoing surgical evacuation and brain biopsy. METHODS: This retrospective single-center cohort study was conducted at the Mount Sinai Health System from 2015 to 2021. Patients with spontaneous ICH who underwent surgical evacuation with brain biopsy and preoperative MRI were included. MRI markers assessed included lobar hemorrhagic lesions (ICH, cerebral microbleeds [CMBs], cortical siderosis [cSS]) and nonhemorrhagic markers (severe visible perivascular spaces in the centrum semiovale [CSO-PVS] and multispot white matter hyperintensities [WMHs]). Pathologic confirmation of CAA was based on modified Vonsattel grading, which evaluates β-amyloid deposition in vessel walls. Diagnostic performance of v2.0 was compared with v1.5 using sensitivity, specificity, and predictive values. Logistic regression models calculated odds ratios (ORs) and 95% CIs for associations between MRI biomarkers and pathologically confirmed CAA. RESULTS: Among 186 patients (median age: 63 years; 38% female), 24% had confirmed CAA. The Boston criteria v2.0 demonstrated higher sensitivity for probable CAA (0.75 vs 0.57) while maintaining specificity (0.96 vs 0.99). For possible CAA, sensitivity improved modestly (0.82 vs 0.77) with comparable specificity (0.84 vs 0.87). Among hemorrhagic markers, cSS (OR 4.14, 95% CI 1.35-13.00, p = 0.013) and lobar CMBs (OR 3.03, 95% CI 1.31-7.10, p = 0.009) were significantly associated with CAA. Among nonhemorrhagic markers, CSO-PVS was strongly associated (OR 5.49, 95% CI 2.37-13.06, p < 0.001) while multispot WMHs were not (OR 1.10, 95% CI 0.45-2.56, p = 0.834). DISCUSSION: The Boston criteria v2.0 enhance sensitivity for diagnosing probable CAA without compromising specificity, largely due to the inclusion of nonhemorrhagic markers such as CSO-PVS. Limitations include the retrospective design, the absence of formal inter-rater reliability measures, and the modest sample size. These findings underscore the potential of v2.0 to improve the diagnostic framework for CAA.
引用
- Downes MH, Kalagara R, Rossitto CP, et al. Validation of the Boston Criteria Version 2.0 for Cerebral Amyloid Angiopathy in Patients Presenting With Intracerebral Hemorrhage. Neurology. 2025. PMID: 40030097. doi:10.1212/WNL.0000000000213460
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。